menu
    • menu
    [{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TP-102","moa":"Enzymes","graph1":"Podiatry","graph2":"Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"8","companyTruncated":"Technophage \/ VectorB2B"},{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"TP-102","moa":"Enzymes","graph1":"Podiatry","graph2":"Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"8","companyTruncated":"Technophage \/ VectorB2B"},{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Eletriptan Hydrobromide","moa":"Serotonin 1b (5-HT1b) receptor | Serotonin 1f (5-HT1f) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"7","companyTruncated":"Technophage \/ VectorB2B"},{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TP-122A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"7","companyTruncated":"Technophage \/ VectorB2B"}]

    Find Clinical Drug Pipeline Developments & Deals by Technophage

    Menu

    Technophage

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Technophage

                            Portugal arrow
                            AllPack Indonesia
                            Not Confirmed

                            Technophage

                            Portugal arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury

                            Details : Eletriptan HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Spinal Cord Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 06, 2024

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Technophage

                            Portugal arrow
                            AllPack Indonesia
                            Not Confirmed

                            Technophage

                            Portugal arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TP-122A

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumon...

                            Details : TP-122A is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pneumonia, Ventilator-Associated.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 17, 2024

                            Lead Product(s) : TP-122A

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Technophage

                            Portugal arrow
                            AllPack Indonesia
                            Not Confirmed

                            Technophage

                            Portugal arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TP-102

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

                            Details : TP-102 is a Microorganism drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            July 17, 2023

                            Lead Product(s) : TP-102

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Technophage

                            Portugal arrow
                            AllPack Indonesia
                            Not Confirmed

                            Technophage

                            Portugal arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TP-102

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers

                            Details : TP-102 is a Microorganism drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 18, 2021

                            Lead Product(s) : TP-102

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth